MCAT topics → Bioenergetics and Metabolism → Cholesterol and Lipoprotein Metabolism

Cholesterol and Lipoprotein Metabolism

MCAT trap: Misidentifies the enzymatic target of statin drugs in cholesterol synthesis. Statins inhibit HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate.

Cholesterol and lipoprotein metabolism is one of those topics where the MCAT tests whether you understand the whole system — not just isolated facts. The most common error: students identify the statin target as squalene synthase instead of HMG-CoA reductase. Statins specifically inhibit HMG-CoA reductase, the rate-limiting committed step that converts HMG-CoA to mevalonate — blocking squalene synthase would be a completely different intervention at a much later step. The core pathway starts in the liver: acetyl-CoA gets converted to HMG-CoA, then HMG-CoA reductase converts it to mevalonate.

The exam hits this topic from multiple angles. Pure recall questions ask you to name the rate-limiting enzyme or identify which lipoprotein performs reverse cholesterol transport. Mechanism questions ask how statins lower LDL or how LDL receptor feedback works at the molecular level. Passage-based questions will describe a patient on a high-fat diet, a statin, or with a genetic LDL receptor defect, and ask you to predict what happens to lipoprotein levels — that requires you to reason through the whole system, not just recall isolated facts.

What makes this tricky is that the logic feels backward in a few places. Students mix up which lipoprotein goes which direction, flip the feedback regulation of LDL receptors, and confuse chylomicrons (dietary origin) with VLDL (hepatic origin). Get the directionality and the feedback loop right, and most MCAT questions on this topic become straightforward.

Common misconceptions

Common mistake
Wrong: Statins inhibit squalene synthase, the enzyme that converts squalene to cholesterol.
Right: Statins inhibit HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate.
Statins do not act on squalene synthase — that enzyme acts much later in the pathway, after the committed step has already occurred. Statins are competitive inhibitors of HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate. This is the rate-limiting, committed step, so blocking it shuts down the entire downstream pathway including squalene and cholesterol production. Remember: statins work early and upstream, not late in the pathway.
Common mistake
Wrong: LDL transports cholesterol from peripheral tissues back to the liver (reverse cholesterol transport).
Right: LDL delivers cholesterol from the liver to peripheral tissues; HDL performs reverse cholesterol transport back to the liver.
LDL and HDL move in opposite directions, and mixing them up will cost you points on both recall and passage questions. LDL is the delivery vehicle — it carries cholesterol from the liver out to peripheral tissues, where cells take it up via LDL receptors. HDL runs the return route, picking up excess cholesterol from peripheral tissues and returning it to the liver for processing — this is called reverse cholesterol transport. A useful anchor: LDL goes out (and accumulates in vessels when in excess), HDL goes back (and is considered 'good' because it clears cholesterol).
Common mistake
Wrong: High intracellular cholesterol upregulates LDL receptor expression to import more cholesterol.
Right: High intracellular cholesterol downregulates LDL receptor expression via SREBP inhibition, reducing further cholesterol uptake.
The logic here is negative feedback, and students often flip it. When intracellular cholesterol is high, the cell has no need for more — so it downregulates LDL receptor expression to stop importing additional cholesterol. This happens through SREBP: when cholesterol is abundant, SREBP is retained in the ER and cannot activate transcription of the LDL receptor gene. When cholesterol is low, SREBP is cleaved and travels to the nucleus to upregulate LDL receptor expression. High cholesterol → less receptor expression → less LDL uptake. This is also why statins work: by reducing cholesterol synthesis, they lower intracellular cholesterol, free up SREBP, upregulate LDL receptors, and pull more LDL out of circulation.
Common mistake
Wrong: Chylomicrons transport endogenously synthesized lipids from the liver to peripheral tissues.
Right: Chylomicrons transport dietary (exogenous) lipids from the intestine; VLDL transports endogenously synthesized lipids from the liver.
Chylomicrons and VLDL are both large, lipid-rich particles, but they come from completely different places and carry different cargo. Chylomicrons are made in intestinal epithelial cells and transport dietary (exogenous) fats absorbed from a meal into the lymph and then bloodstream. VLDL is made in the liver and transports endogenously synthesized lipids (triglycerides and cholesterol made by the liver) out to peripheral tissues. The key distinction is origin: gut → chylomicrons (dietary), liver → VLDL (endogenous).
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know that HMG-CoA reductase is the rate-limiting enzyme in cholesterol synthesis, that statins specifically inhibit this enzyme (not a later step like squalene synthase), and how SREBP transcription factor regulation connects intracellular cholesterol levels to enzyme expression.
  2. Be able to rank and distinguish the five main lipoprotein classes — chylomicrons, VLDL, IDL, LDL, HDL — by density, lipid-to-protein ratio, origin, and the direction they transport lipids (dietary vs. endogenous; liver to periphery vs. periphery back to liver).
  3. Understand LDL receptor-mediated endocytosis: how cells take up LDL, how high intracellular cholesterol downregulates both HMG-CoA reductase and LDL receptor expression through SREBP inhibition, and what goes wrong in familial hypercholesterolemia.
  4. Apply the pathway to predict outcomes: if a patient takes a statin, starts a high-fat diet, or has a genetic LDL receptor defect, trace through the effects on HMG-CoA reductase activity, LDL receptor expression, and circulating LDL levels.

Can you avoid these mistakes?

A patient with familial hypercholesterolemia has non-functional LDL receptors. Predict what happens to: (1) circulating LDL levels, (2) intracellular cholesterol in liver cells, and (3) HMG-CoA reductase activity. Explain the chain of logic.
A new drug is developed that inhibits squalene synthase. A student claims this drug works by the same mechanism as statins. What's wrong with that claim, and how would the effects of the two drugs differ in terms of which step each blocks?
Rank chylomicrons, LDL, and HDL from lowest to highest density, and for each one state: where it is made, what it primarily carries, and where it delivers its cargo.
A person eats a high-cholesterol diet for several weeks. Using SREBP regulation, explain how their liver cells would respond at the level of (1) HMG-CoA reductase expression and (2) LDL receptor expression. Would circulating LDL levels go up or down?

Related topics

Lipid Structure (TAGs, Phospholipids, Sphingolipids, Steroids) Bioenergetics — Free Energy, Equilibrium, Coupling ATP, Phosphoryl Transfer, and Redox Reactions Carbohydrate Nomenclature and Cyclic Structures Glycolysis (Steps, Regulation, Net Yield)

See how your Anki deck covers this topic.

Upload your deck for a free audit →